Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial
/in Dendritic Cells, International Publications, Malignant MelanomaSuppression of TGF-β and IL-10 receptors on self-differentiated dendritic cells by short-hairpin RNAs enhanced activation of effector T-cells against cholangiocarcinoma cells
/in Dendritic Cells, Gallbladder Cancer, International PublicationsBreast cancer stem cell RNA-pulsed dendritic cells enhance tumor cell killing by effector T cells
/in Breast Cancer, Dendritic Cells, International PublicationsTherapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update
/in Dendritic Cells, International PublicationsCombined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors
/in Dendritic Cells, Glioblastoma, International PublicationsProphylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model
/in Dendritic Cells, International Publications, Pancreatic CancerPersonalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models
/in Dendritic Cells, International PublicationsEngineering dendritic cell vaccines to improve cancer immunotherapy
/in Dendritic Cells, International PublicationsA Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
/in Dendritic Cells, International Publications, Ovarian Cancer
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer